Phenoxybenzamine

This classification denotes a carcinogenic aromatic amine and alpha-adrenergic blocking agent with the molecular formula C18H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0TTZ664R7Z, chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, hydrochloride but generally known as phenoxybenzamine, which bears US NIH Compound Identifier 4768. European Medicines Agency schedules Phenoxybenzamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09778MIG. The term PHENOXYBENZAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). World Health Organization schedules phenoxybenzamine in its Anatomical Therapeutic Chemical (ATC) Classification. PHENOXYBENZAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule phenoxybenzamine under HS 29221980 and SITC 51461. As of Q4 2014, PHENOXYBENZAMINE remains the US FDA Preferred Term for this commodity. Phenoxybenzamine bears US NLM identifiers UMLS ID C0031441 and NCI Concept Code C62065. SMILES: CLCCN(C(COC1CCCCC1)C)CC1CCCCC1.